Calcitonin; Related Peptides Patents (Class 530/307)
-
Patent number: 5214030Abstract: A method of treating erectile dysfunctions in mammals and men, by administering to the mammal or man a pharmaceutical composition comprising a therapeutically effective amount of a calcitonin gene-related peptide.Type: GrantFiled: October 18, 1991Date of Patent: May 25, 1993Inventor: Georg Stief
-
Patent number: 5204326Abstract: Novel polypeptide derivatives, acid-addition salts thereof and complexes thereof, having the activities for inhibiting bone calcium absorption, for lowering the blood level of calcium, as analgesics, for inhibiting secretion of the gastric juice.Pharmaceutical composition can be prepared by formulating, at least one of the novel polypeptide derivatives, acid-addition salts thereof and complexes thereof, together with a proteolytic enzyme inhibitors and/or pharmaceutically acceptable acids.The pharmaceutical composition are quite effective as agents for curing hypercalcemia, for curing Peget's disease, for curing osteoporosis, analgetic agent, anti-ulcerative agent and the like.Type: GrantFiled: March 14, 1990Date of Patent: April 20, 1993Assignees: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc.Inventors: Setsuro Fujii, deceased, by Keiko Fujii, successor, by Shinichiro Fujii, successor, by Kaoruko Takada, successor, Yoshihito Yamamoto, Fumio Shimizu, Masatoshi Inai, Naosumi Kinoshita, Shizuo Nakamura, Mitsuru Hirohashi, Takashi Sakamoto, Kazuhiko Tsutsumi, Tetsuhiko Shirasaka
-
Patent number: 5175146Abstract: Synthetic hypocalcemic peptides which are similar in biological properties to native calcitonins as clinically useful agents. The peptides comprise analogues of native calcitonins having amino acid substitutions and deletions which act to improve potency, prolong duration of the hormonal effect, enhance receptor binding, and increase oral or nasal bioavailability. The calcitonin peptide analogues are less expensive and more easily synthesized than native calcitonins, and have improved resistance to inactivation or degradation. Methods are provided for the synthesis of these peptides.Also, disclosed are novel cyclic peptides, including calcitonin, having increased stability with respect to proteolysis. Methods for the synthesis of these peptides are provided, comprising converting disulfide cyclic peptides and proteins to enzymatically and chemically stable cyclic peptide structures by the replacement of cysteine residues with dicarboxylic acids and diamino acids.Type: GrantFiled: August 24, 1990Date of Patent: December 29, 1992Assignee: Vical, Inc.Inventors: Channa Basava, Karl Y. Hostetler
-
Patent number: 5169933Abstract: Covalently-linked complexes (CLCs) for targeting a defined population of cells, comprising a targeting protein; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLC-target cell interaction are disclosed. Methods for using the claimed CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging are also described.Type: GrantFiled: August 7, 1989Date of Patent: December 8, 1992Assignee: NeoRx CorporationInventors: David C. Anderson, A. Charles Morgan, Jr., Paul G. Abrams, Alan R. Fritzberg, Everett J. Nichols
-
Patent number: 5162305Abstract: Novel synthetic polypeptide derivatives, i.e., novel calcitonin derivatives, having improved basic physiological activities of the corresponding natural calcitonins, i.e., the activity for lowering the blood level of calcium, the activity as an analgesic, as well as the activity for inhibiting the secretion of the gastric juice. Thus these synthetic calcitonins are effective as agents for curing hypercalcemia, analgetic agents, anti-ulcerative agents and the like.Type: GrantFiled: February 23, 1989Date of Patent: November 10, 1992Assignees: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc.Inventors: Setsuro Fujii, Yoshihito Yamamoto, Fumio Shimizu, Masatoshi Inai, Mitsuru Hirohashi
-
Patent number: 5153308Abstract: Calcitonin derivatives wherein at least one of the first cysteine residue and the seventh cysteine residue is S-sulfonated; processes for the production of the calcitonin derivatives comprising the steps of reacting a calcitonin with a sulfite anion or both a sulfite anion and an oxidizing agent to form the S-sulfonated derivative, and recovering the sulfonated calcitonin derivative; a pharmaceutical composition comprising the S-sulfonated calcitonin derivative; and a method of treating a patient having a disease wherein a decrease of a serum calcium level is desired, by administering the S-sulfonated calcitonin derivative to the patient.Type: GrantFiled: June 7, 1989Date of Patent: October 6, 1992Assignee: Teijin LimitedInventors: Takashi Sugiyama, Takashi Kamimura, Kenichi Masuda, Yoji Suzuki
-
Patent number: 5149779Abstract: Peptide analogues of human humoral hypercalcemic factor (hHCF) that contain a lactam bridge act as inhibitors of the naturally occurring peptide. A lactam bridge between Lys and Asp situated five residues (inclusive) apart confers rigidity to that region of the peptide, and enhances the helical nature and metabolic stability of the peptide analogue.Type: GrantFiled: July 26, 1990Date of Patent: September 22, 1992Assignee: Merck & Co., Inc.Inventors: Michael Chorev, Eli Roubini
-
Patent number: 5122376Abstract: Compositions comprising a calcitonin gene related peptide and, as an absorption enhancer, a glycyrrhizinate.Type: GrantFiled: May 9, 1990Date of Patent: June 16, 1992Assignee: ISF Societa per AzioniInventors: Valerio Aliverti, Luciano Dorigotti, Teodoro Fonio, Mario Pinza
-
Patent number: 5049654Abstract: A compound of the formula ##STR1## wherein Y is sulfur or methylene and A is Asn or Asp, or a pharmaceutically acceptable salt thereof is useful for the treatment of calcium metabolic disorders, cardiac disease and ulcers, and for the improvement of cranial circulation.Type: GrantFiled: December 4, 1987Date of Patent: September 17, 1991Assignee: Toyo Jozo Kabushiki KaishaInventors: Kaoru Morita, Toyonobu Uzawa, Masayuki Hori, Toshiharu Noda
-
Patent number: 5026825Abstract: Disclosed are intranasal formulations comprising calcitonin and .sup..DELTA. -aminolevulinic acid in a pharmaceutically acceptable excipient.Type: GrantFiled: September 8, 1988Date of Patent: June 25, 1991Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Peter E. Grebow, Herschel H. Li, Lewis J. Klunk, Jr.
-
Patent number: 5010174Abstract: There is disclosed a calcitonin derivative and its salt, comprising an amino acid residue at the 1-position of calcitonin which is a cyclic amino acid residue represented by the formula: ##STR1## wherein X represents a sulfur atom or a methylene group; and n represents an integer of 0 or 1. and an amino acid residue at the 7-position which is a cysteine residue which may be substituted with an appropriate protective group.Type: GrantFiled: May 17, 1989Date of Patent: April 23, 1991Assignee: Mitsubishi Petrochemical Co., Ltd.Inventors: Sachio Hirose, Motomu Hane, Masanobu Inagawa
-
Patent number: 5002771Abstract: Disclosed are rectal and vaginal suppository formulations comprising calcitonin and caprylic acid monoglyceride in a pharmaceutically acceptable suppository vehicle.Type: GrantFiled: February 3, 1989Date of Patent: March 26, 1991Assignee: Rorer Pharmaceutical Corp.Inventors: Abdur R. Purkaystha, Gary G. Gazdick, Jay E. Dorrell, Keith C. Mozzone, Howard J. Levin
-
Patent number: 5001222Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a histidine in position 17. The position 17 histidine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: May 23, 1988Date of Patent: March 19, 1991Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Ronald C. Orlowski, Robert L. Colescott
-
Patent number: 4992530Abstract: A compound of the formula ##STR1## wherein R is H or H-Ala-NH- and when A is Asp, B is Asp or Glu, C is Leu and D is Val; when A is Asn and B is Gly, C is Phe and D is Gly; when A is Asn, B is Asp or Glu and C is Leu, D is Gly; and when A is Asn, B is Asp or Glu, and C is Phe, D is Val, or a pharmaceutically acceptable salt thereof, is useful for the treatment of calcium metabolic disorders, cardiac disease and ulcers, and for the improvement of cerebral circulation.Type: GrantFiled: July 21, 1988Date of Patent: February 12, 1991Assignee: Toyo Jozo Kabushiki KaishaInventors: Kaoru Morita, Toyonobu Uzawa, Masayuki Hori, Toshiharu Noda
-
Patent number: 4845080Abstract: The invention relates to a substance from the calcitonin group, which substance can be isolated from the human body or can be obtained in a different manner, but clearly differs from the known human calcitonin-(1-32), the said substance having hypocalcaemic activity.Type: GrantFiled: September 26, 1986Date of Patent: July 4, 1989Assignee: Ciba-Geigy CorporationInventor: Jan A. Fischer
-
Patent number: 4824936Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an alanine in position 19 instead of the natural leucine or phenylalanine found in those positions. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: May 6, 1987Date of Patent: April 25, 1989Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Glenn L. Stahl, Robert L. Colescott
-
Patent number: 4820811Abstract: A complex of a therapeutic agent is disclosed in which the therapeutic agent is complexed to an ammonium ion selected from the group consisting of ##STR1## where R.sup.1 and R.sup.2 are the same or different and are alkyl or hydroxy substituted alkyl containing 1 to 6 carbon atoms; andR, R' and R" are the same or different and are saturated or unsaturated aliphatics containing at least 10 carbon atoms, ##STR2## where R.sup.1, R.sup.2 and R" are as defined above, ##STR3## where R.sup.3 is independently alkyl or hydroxy substituted alkyl containing at least 10 carbon atoms; and R.sup.1, R.sup.2, R.sup.3 and R' having the meanings given above; and ##STR4## where R.sup.1, R.sup.2 and R.sup.3 have the meanings given above. The therapeutic agent is heparin, a biologically active peptide or protein or an antineoplastic drug. The therapeutic agent may also be covalently bonded to a triglyceride type backbone to form a compound.Type: GrantFiled: December 4, 1986Date of Patent: April 11, 1989Assignee: Research CorporationInventor: Lin-nar L. Teng
-
Patent number: 4820804Abstract: New hypocalcaemic peptides are disclosed of the formula ##STR1## wherein X represents H for the replacement of the N alpha amino group or acyl groups for the acylation of the N alpha amino group, the N-alpha amino group. The acyl groups are carboxylic acids especially formic, acetic, propionic, buteric, valeric, hexanoic, heptanoic, octanoic, and nonanoic acids or their respective isomers, L-lactic acid and the half amides of malonic, succinic, glutaric and adipic acids. Y is L-valine, glycine, L-methionine, L-alanine, L-leucine or L-isoleucine.Type: GrantFiled: April 21, 1987Date of Patent: April 11, 1989Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Jay K. Seyler, James E. Geever, Everett Flanigan
-
Patent number: 4804742Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which are amide analogs of natural calcitonins.Type: GrantFiled: December 5, 1986Date of Patent: February 14, 1989Assignee: Rorer Pharmaceutical CorporationInventors: Edward S. Neiss, David Stevenson, Laurence L. Ho, Robert C. Liu, John T. Suh
-
Patent number: 4785080Abstract: A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Sample; a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentration of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte to be directly related to the conversion of the substrate to the reporter molecule.Type: GrantFiled: August 29, 1985Date of Patent: November 15, 1988Assignee: Baker Instruments CorporationInventors: Peter R. Farina, James R. Golke
-
Patent number: 4764590Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 19, a glutamine in position 20, or a threonine in position 21. All three amino acids are omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: April 21, 1987Date of Patent: August 16, 1988Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4764589Abstract: New hypocalcaemic peptides are disclosed of the formula ##STR1## wherein X represents acyl groups for the acylation of the N alpha-amino group and the radicals of carboxylic acids especially of formic, acetic, propionic, buteric, valeric, hexanoic, heptanoic, octanoic, and nonanoic acids along with all their respective isomers. We also wish to include L-lactic acid along with the half amides of malonic, succinic, glutaric and adipic acids.Type: GrantFiled: May 26, 1987Date of Patent: August 16, 1988Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4764591Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 19, a glutamine in position 20, a threonine in position 21, and a tyrosine in position 22. All four amino acids are omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: April 21, 1987Date of Patent: August 16, 1988Assignee: Rorer Pharmaceutical CorporationInventors: Ronald C. Orlowski, Jay K. Seyler, Everett Flanigan
-
Patent number: 4758550Abstract: A compound of formula I ##STR1## wherein R is H or R'CO wherein R'CO is an acyl radical of a carboxylic acid,Y.sub.1 is the radical linked to an alpha carbon atom an .alpha.-amino acid,Y.sub.2 is the radical linked to an alpha carbon atom of an .alpha.-amino acid, ##STR2## --CH.sub.2 --S--S--CH.sub.2 --CH.sub.2 --COOH, --(CH.sub.2).sub.p --COOH or --CH.sub.2 --S--Y.sub.3,Y.sub.3 is (C.sub.1-4)alkyl or benzyl optionally substituted by methyl or methoxy,or CH.sub.3 CO--NH--CH.sub.2 --,n is 1 to 4,A.sub.6 is Thr or D-Thr,p is 3 to 5,A.sub.8 is the aminoacyl radical of a neutral, lipophilic L-.alpha.-aminoacid,A.sub.9 is the aminoacyl radical of a neutral, lipophilic L- or D-.alpha.-aminoacid,Z is a polypeptide radical corresponding to the polypeptide radical in positions 10 to 31 of a natural calcitonin or a derivative or analogue thereof having a hypocalcemic effect,wherein, when there is more than one Y.sub.1 radical, these are the same or different, and with the exception of radical A.sub.Type: GrantFiled: December 3, 1986Date of Patent: July 19, 1988Assignee: Sandoz Ltd.Inventors: Francois Cardinaux, Janos Pless, Robert H. Buck
-
Patent number: 4746728Abstract: New peptides are disclosed which have biological activity of the same type as the known calcitonins and which have a glycine at position 8 instead of the natural valine found in that position. In addition these new peptides do not have a leucine in position 19. The position 19 leucine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: May 5, 1986Date of Patent: May 24, 1988Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4743677Abstract: A peptide represented by the following formula: ##STR1## wherein Y means a sulfur atom or methylene group, A stands for Asp or Asn, B denotes Val or Met and C is Asn or Ser, or a salt thereof.Type: GrantFiled: August 5, 1986Date of Patent: May 10, 1988Assignee: Toyo Jozo Co., Ltd.Inventors: Toshiharu Noda, Nobutaka Fujii, Kaoru Morita, Masayuki Hori
-
Patent number: 4732969Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 19 or a glutamine in position 20. Both amino acids are omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: May 5, 1986Date of Patent: March 22, 1988Assignee: Armour Pharmaceutical CorporationInventors: Ronald C. Orlowski, Jay K. Seyler, James E. Geever
-
Patent number: 4720483Abstract: Described are peptides that have, as partial sequence of a larger peptide, or exclusively, the amino acid sequence of the formula I ##STR1## in which the cysteine residues can form intra- or inter-molecular disulphide bridges, and derivatives thereof having an amidated terminal carboxy group and/or an acylated terminal amino group, and their salts, DNA sequences that code for the mentioned peptides, micro-organisms that contain these DNA sequences, processes for the manufacture thereof, pharmaceutical preparations that contain the mentioned peptides in the form of their amides, and the use of these peptide-amides for the treatment of coronary circulation disorders and bone metabolism disorders.Type: GrantFiled: January 15, 1986Date of Patent: January 19, 1988Assignee: Ciba-Geigy CorporationInventors: Hendrik S. Jansz, Cornelis J. M. Lips, Paul H. Steenbergh, Hans Rink, Peter Sieber
-
Patent number: 4709014Abstract: A peptide with C-terminal proline amide is produced by reacting in aqueous solution a protein substrate having C-terminal prolyl-leucine, prolyl-isoleucine, prolyl-valine, or prolyl-phenylalanine with carboxypeptidase Y in the presence of ammonia. The ammonia is preferably generated by the aqueous reaction of an ammonium salt and an alkali. An example of the peptide product is human calcitonin.Type: GrantFiled: April 1, 1986Date of Patent: November 24, 1987Assignee: Sankyo Company LimitedInventor: Hidetsune Tamaoki
-
Patent number: 4703106Abstract: There are disclosed a novel polypeptide represented by the formula shown below or its acid addition salt or complex: ##STR1## wherein Ala represents alanine, Ser serine, Leu leucine, Thr threonine, Val valine, Gly glycine, Lys lysine, Gln glutamine, Glu glutamic acid, His histidine, Tyr tyrosine, Pro proline, Arg arginine, Asp aspartic acid, and n represents an integer of 3 to 7,and a process for producing the same comprising forming a peptide or polypeptide represented by the above formula and subjecting the structural units containing a peptide residue represented by the formula: ##STR2## wherein R represents an active ester residue, Ala, Ser, Leu, Thr and n have the same meanings as defined above,formed in any step of the reaction to cyclization reaction.Type: GrantFiled: November 4, 1985Date of Patent: October 27, 1987Assignees: Mitsubishi Petrochemical Co., Ltd., Mitsubishi Chemical Industries, Ltd., Sanyo Fine Co., Ltd.Inventors: Sachio Hirose, Tammotsu Homma, Takashi Kurihara, Hidenari Adachi, Yoshitaka Sako, Makiko Shibata
-
Patent number: 4663309Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is a moiety selected from the group consisting of ##STR2## R.sub.2 -R.sub.22 are amino acid moieties wherein R.sub.2 is an optional moiety which when present is selected from the group consisting of Ser and Gly,R.sub.8 is Leu or Val,R.sub.10 is Gln, Lys, or Gly,R.sub.11, R.sub.14, and R.sub.20 are each independently selected from the group consisting of Gln and Lys,R.sub.12 is Leu or Trp,R.sub.13 is Gln or Ser,R.sub.17 is Gln or His,R.sub.19 is Leu or Cys,R.sub.21 is Gln or Thr,R.sub.22 is an optional moiety which when present is selected from the group consisting of Leu and Tyr;R.sub.24 -R.sub.Type: GrantFiled: February 27, 1985Date of Patent: May 5, 1987Assignee: University Patents, Inc.Inventors: Emil T. Kaiser, Gregory R. Moe
-
Patent number: 4659804Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a disulfide bond connecting the cysteines at positions one and seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin partially protected peptides.Type: GrantFiled: November 1, 1984Date of Patent: April 21, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Robert L. Colescott, Glenn L. Stahl, Takashi Enkoji, James E. Geever, Everett Flanigan
-
Patent number: 4658014Abstract: New peptides are disclosed which have biological activity of the same type as calcitonins and which have been modified with desaminocysteine and .alpha.-aminosuberic acid at the N-terminal and new amino acid substituents at the penultimate position of the C-terminal.Type: GrantFiled: December 20, 1985Date of Patent: April 14, 1987Inventor: Tomas G. Kempe
-
Patent number: 4652627Abstract: New calcitonin analogs are disclosed which have biological activity of the same type as known calcitonins and which have a D-amino acid substituent in at least one of the positions 31 and 32 instead of the natural L-amino acid units. The calcitonin analog may be analogs of salmon, eel, chicken, bovine, porcine, ovine, murine or human calcitonins.Type: GrantFiled: August 16, 1985Date of Patent: March 24, 1987Inventors: Tomas G. Kempe, Flora Chow
-
Patent number: 4650854Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which are amide analogs of natural calcitonins.Type: GrantFiled: June 6, 1985Date of Patent: March 17, 1987Assignee: USV Pharmaceutical CorporationInventors: Edward S. Neiss, David Stevenson, Laurence L. Ho, Robert C. Liu, John T. Suh
-
Patent number: 4644054Abstract: New polypeptides are disclosed which have biological activity of the same degree as known calcitonins and which have amino acid substituents in position 31 instead of the naturally occuring amino acids--Thr, Ala, Val.Type: GrantFiled: October 1, 1985Date of Patent: February 17, 1987Inventor: Tomas G. Kempe
-
Patent number: 4639509Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an alanine in positions 16 and 19 instead of the natural leucine or phenylalanine found in those positions. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: March 28, 1985Date of Patent: January 27, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Glenn L. Stahl, Robert L. Colescott
-
Patent number: 4639511Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 19. The position 19 leucine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: November 12, 1985Date of Patent: January 27, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4639510Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an S-acetamidomethyl cysteine at one and an alanine at seven, or an alanine at one and an S-acetamidomethyl cysteine at seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin-type peptides.Type: GrantFiled: October 4, 1985Date of Patent: January 27, 1987Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4632978Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins; which have a serine in position 6 while the position 19 leucine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: October 15, 1985Date of Patent: December 30, 1986Assignee: Armour Pharmaceutical Corp.Inventors: Jay K. Seyler, Ronald C. Orlowski
-
Patent number: 4623716Abstract: Peptides, such as calcitonin, having two cysteine residues connected by a disulfide bond are prepared by a process which includes the step of cyclizing the cysteines at a pH of 8.5 to 9.0, and a concentration of 0.4 to 1.8 mg of peptide per ml of solution. These novel conditions produce rapid cyclization with an unforeseen improvement in yield.Type: GrantFiled: November 1, 1984Date of Patent: November 18, 1986Assignee: USV Pharmaceutical Corp.Inventors: David Stevenson, Mohammad A. Islam
-
Patent number: 4622387Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have an methionine in position 8 instead of the natural valine found in that position. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: June 19, 1985Date of Patent: November 11, 1986Assignee: Armour Pharmaceutical Co.Inventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4622388Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a serine in position 2 nor an asparagine in position 3. Both serine 2 and asparagine 3 are omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: November 12, 1985Date of Patent: November 11, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4622386Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have cysteines at positions one and seven. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin-type peptides.Type: GrantFiled: March 28, 1985Date of Patent: November 11, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4606856Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and do not have an amino group on cysteine one and also are substitution analogs of the natural calcitonins. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: March 18, 1985Date of Patent: August 19, 1986Inventors: Jay K. Seyler, Ronald C. Orlowski
-
Patent number: 4605515Abstract: New peptides ae disclosed which have biological activity of the same type as known calcitonins and contains only twenty-three amino acids rather than the normally occurring thirty-two amino acids. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: October 24, 1984Date of Patent: August 12, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Glenn L. Stahl
-
Patent number: 4605514Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a leucine in position 4. The position 4 leucine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: September 24, 1984Date of Patent: August 12, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: 4604236Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a serine in position 13. The position 13 serine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: March 18, 1985Date of Patent: August 5, 1986Inventors: Ronald C. Orlowski, Jay K. Seyler
-
Patent number: 4604238Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which have a shorter amino acid chain than natural calcitonins and are also substitution analogs of the natural calcitonins. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.Type: GrantFiled: December 10, 1984Date of Patent: August 5, 1986Assignee: Armour Pharmaceutical CompanyInventors: Ronald C. Orlowski, Jay K. Seyler, Glenn L. Stahl
-
Patent number: RE32347Abstract: Human calcitonin in the form of four components and process for their isolation from C-cells material.Type: GrantFiled: August 27, 1984Date of Patent: February 3, 1987Assignee: Ciba-Geigy Corp.Inventors: Robert Neher, Bernhard Riniker